

Synthesis of methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl) carbonylamino] alkananoates and methyl 2-[2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonyl-amino]alkanamido] alkananoate

Walid Fathalla*^a and Pavel Pazdera^b

^aPhysics and Math. Engineering Dept., Faculty of Engineering, Port-Said University, Port Said, Egypt.

^bCentre for Syntheses at Sustainable Conditions and Their Management, Faculty of Science, Masaryk University, Brno, Czech Republic

E-mail: walid3369@yahoo.com


Received 11-20-2016

Accepted 03-07-2017

Published on line 05-14-2017

Abstract

A series of methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] alkananoates **7a-f** has been developed by the direct condensation of ethyl [4-hydroxy-2-oxo--1-phenyl-1,2-dihydro-3-quinoline] carboxylate **4** with amino acid ester hydrochloride in the presence of triethylamine. The quinoline amino acid esters **7a-f** were the key intermediate for the preparation of a series of methyl 2-[2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino]alkanamido] alkananoate **10-13(a-f)** *via* azide coupling method with amino acid ester.




Keywords: Amino acid esters, DCC coupling method, azide coupling method, direct amino acid condensation, anisotropy, intramolecular hydrogen bond interactions, linomide

Introduction

Quinoline is a very important *N*-heteroaromatic compound known to possess a wide variety of pharmacological activities¹ such as. antimalarial,² antibacterial,^{3,4} antituberculosis,⁵ anticancer activity,^{6,7} analgesic activity,⁸ anti-inflammatory activity,⁸ anti-rheumatic,⁹ antinephritic,¹⁰ or in treating Alzheimer's disease (AD).¹¹

Linomide (roquinimex), immunomodulator drug showed a wide variety of effective applications in immunotherapy of tumors,^{12,13} has a profound inhibitory influence in several experimental autoimmune diseases, including acute and chronic experimental allergic encephalomyelitis¹⁴ and has a potential for the treatment of multiple sclerosis.¹⁵




Roquinimex (Linomide)

Non-proteinogenic amino acids are major component in a number of drugs including β -lactam antibiotics¹⁶ and glutamate antagonists.¹⁷ The attachment of new heterocyclic compounds to amino acid esters and dipeptide might provide structures with interesting conformation, stability and biological activity.


Results and Discussion

We now report the preparation of methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl) carbonylamino] alkanoates and dipeptide ester derivatives. The ester **4** was prepared by a series of sequential reactions starting with Ulmann condensation of *o*-chlorobenzoic acid **1** with aniline in the presence of K_2CO_3 and CuO to give *N*-phenylsubstituted anthranilic acid **2**¹⁸ that subsequently reacted with ethyl chloroformate in the presence of triethylamine to afford the *N*-phenyl substituted isatoic anhydride **3**. Isatoic anhydride **3** was condensed with diethyl malonate in the presence of NaH in DMF to afford ethyl [4-hydroxy-2-oxo-1-phenyl-1,2-dihydro-3-quinoline] carboxylate **4** in 74% yield.¹⁹ Hydrazinolysis of the ester **4** was achieved by refluxing **4** in the presence of hydrazine hydrate in ethanol for 4 h. and gave the hydrazide **5**. The hydrolysis of this ester **4** to give the carboxylic acid derivative **6** was only possible by acid hydrolysis using HCl and acetic anhydride at 60 °C for 6h.²⁰ to give the pure carboxylic acid **6** in good yield. (normal saponification in basic medium and acidic medium gave mixture of products), Scheme 1.



Scheme 1

Coupling amino acid residue to quinoline ring system to afford the target compounds methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] alkanoate **7a-f** could be achieved from compounds **5** and **6** via Azide and DCC coupling methods, respectively. Unfortunately, these coupling methods gave negative results probably due to hydrogen bond interaction between the $\text{C}=\text{O}$ and OH located at position 4. The only positive result was achieved by coupling the carboxylic acid derivative **6** with amino acid ester hydrochloride in CHCl_3 and in the presence thionyl chloride and triethylamine at 0°C for 4h.²⁰ The desired product **7a-f** was obtained after column separation in poor yield (6-18% yield) we also noticed that the starting acid was not completely consumed (TLC monitored), Scheme 2. We tried to improve the yield of this reaction but more problems started to appear when we extended the time of the reaction or when we raised the temperature. Our efforts for the preparation of **7a-f** in high yields was successful using the direct reaction of amino acid esters with the ester **4**. Thus, condensation of ethyl [4-hydroxy-2-oxo-1-phenyl-1,2-dihydro-3-quinoline] carboxylate **4** with amino acid ester hydrochloride in the presence of triethylamine in toluene under reflux condition for 6 h. gave the amino acid derivatives **7a-f** in high yield (65-93%), Scheme 2.



Scheme 2

The structure assignment of amino acid derivatives **7a-f** is based on ¹H and ¹³C NMR spectroscopy as well as physicochemical analysis, Figure 1. Thus, the ¹H NMR spectrum of **7a** exhibits two interesting singlet signals at δ 16.67 and 10.55 ppm corresponding to OH and NH groups, respectively. These rather down fielded shifts are due to intramolecular hydrogen bond interaction of the type O-H...O=C and N-H...O=C, respectively. The ¹H NMR spectrum of **7a** exhibits an interesting doublet signal at δ 8.26 ppm due to anisotropic shielding of the neighboring carbonyl on an aromatic proton. All three chemical shifts mentioned earlier are common for all amino acid derivatives **7a-f** which confirms the fixed planar structure. The ¹H NMR spectrum also shows signals at δ 4.20, 3.78 ppm typically associated with the NHCH₂ and OCH₃ groups of the glycine residue. The ¹³C NMR spectrum of **7a** reveals quaternary carbon signals at δ 172.6, 171.4 and 169.4 ppm assigned to C=O ester, C-OH and C=O amide respectively. The ¹³C NMR spectrum of **7a** also reveals signals at δ 52.4 and 40.9 ppm associated with OCH₃ and NHCH₂, respectively, figure 1.





Figure 1. Selected ¹H and ¹³C NMR spectral data of methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] acetate **7a**.

Our next target was structure modification of quinoline ring system by attachment of a series dipeptides to give a series of methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)alkanamido]alkanoate **10-13(a-f)**. The synthesis of the target dipeptide derivatives **10-13(a-f)** were efficiently formed from the key amino acid ester derivatives **7a-f** via azide coupling method. Thus, amino acid derivatives **7a-d** were boiled with hydrazine hydrate in ethyl alcohol to afford the hydrazides **8a-d**, which were subsequently converted into azides **9a-d** by treatment with NaNO₂ and HCl mixture. The *in situ* generated azide derivative **9a-d** in ethyl acetate was used in a *one-pot* strategy without purification nor isolation. The azide **9a-d** solution in ethyl acetate was reacted with amino acid methyl ester hydrochloride in the presence of triethylamine to afford methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)alkanamido]alkanoate **10-13(a-f)** in good yield, scheme 3. The presence of amino acid spacer prevented the intramolecular hydrogen bond interaction from interfering the coupling reaction as in case of direct coupling of the hydrazide **5**.



10-13	n ₁	R ¹	n ₂	R ²	abb.	10-13	n ₁	R ¹	n ₂	R ²	abb.
10a	0	H	0	H	Gly-Gly	10d	0	H	1	H	Gly-β-Ala
10b	0	H	0	CH ₃	Gly-Ala	10e	0	H	0	Ph	Gly-Phg
10c	0	H	0	CH ₂ CH(CH ₃) ₂	Gly-Leu	10f	0	H	0	(CH ₂) ₂ COOCH ₃	Gly-Glu
11a	0	CH ₃	0	H	Ala-Gly	11d	0	CH ₃	1	H	Ala-β-Ala
11b	0	CH ₃	0	CH ₃	Ala-Ala	11e	0	CH ₃	0	Ph	Ala-Phg
11c	0	CH ₃	0	CH ₂ CH(CH ₃) ₂	Ala-Leu	11f	0	CH ₃	0	(CH ₂) ₂ COOCH ₃	Ala-Glu
12a	0	CH ₂ CH(CH ₃) ₂	0	H	Leu-Gly	12d	0	CH ₂ CH(CH ₃) ₂	1	H	Leu-β-Ala
12b	0	CH ₂ CH(CH ₃) ₂	0	CH ₃	Leu-Ala	12e	0	CH ₂ CH(CH ₃) ₂	0	Ph	Leu-Phg
13a	1	H	0	H	β-Ala-Gly	13d	1	H	1	H	β-Ala-β-Ala
13b	1	H	0	CH ₃	β-Ala-Ala	13e	1	H	0	Ph	β-Ala-Phg
13c	1	H	0	CH ₂ CH(CH ₃) ₂	β-Ala-Leu	13f	1	H	0	(CH ₂) ₂ COOCH ₃	β-Ala-Glu

Scheme 3

The structure assignment of dipeptide derivatives **10-13(a-f)** is based on ¹H and ¹³C NMR spectroscopy as well as physicochemical analysis, Figure 2. Thus the ¹H NMR spectrum of **10a** exhibits two interesting singlet

signals at δ 16.54 and 10.55 ppm corresponding to OH and NH groups, respectively. The ^1H NMR spectrum of **10a** exhibits an interesting doublet signal at δ 8.25 ppm due an aromatic proton. All three chemical shifts mentioned gave similar results with the amino acid derivative **7a-f** and are common for all dipeptide derivatives **10-13(a-f)**, which confirms the fixed planar structure. The ^1H NMR spectrum also shows signals at δ 4.17, 3.75 ppm typically associated with 2NHCH_2 and OCH_3 groups of both glycine residues. The ^{13}C NMR spectrum of **10a** reveals quaternary carbon signals at δ 172.7, 171.8, 170.0, 168.6 and 162.9 ppm assigned to C=O ester, C-OH and $3\text{C}=\text{O}$ amide respectively. The ^{13}C NMR spectrum of **10a** also reveals signals at δ 52.3, 45.0 and 41.3 ppm associated with OCH_3 and 2NHCH_2 , respectively, figure 2.




Figure 2. Selected ^1H and ^{13}C NMR spectral data of methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)acetamido]acetate **10a**.

Conclusions

A direct condensation of amino acid esters with ethyl [4-hydroxy-2-oxo--1-phenyl-1,2-dihydro-3-quinoline] carboxylate **4** in the presence of triethylamine gave a series of quinoline amino acid derivatives **7a-f**. The quinoline amino acid esters **7a-f** were the key intermediate for the preparation of a series of methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl) carbonylamino)alkanamido] alkanooate **10-13(a-f)** *via* azide coupling method with amino acid ester.

Acknowledgements

We would like to Thank Department of Organic Chemistry Faculty of Science Masaryk University, Brno, Czech Republic and Ministry of high education, Egypt for funding this research proposal.

Experimental Section

General. Solvent were purified and dried by standard procedures. The boiling range of the petroleum ether used was 40-60 °C. Thin layer chromatography (TLC): silica gel 60 F₂₅₄ plastic plates (E. Merck, layer thickness 0.2 mm) detected by UV absorption. Elemental analyses were performed on a *Flash EA-1112* instrument at the Microanalytical laboratory, Faculty of Science, Suez Canal University, Ismailia, Egypt. Melting points were determined on a Buchi 510 melting-point apparatus and the values are uncorrected. ^1H and ^{13}C NMR spectra

were recorded at 300 MHz and 75.5 MHz, respectively (Bruker AC 300) in CDCl₃ and DMSO solution with tetramethylsilane as an internal standard. The NMR analysis were performed at Organic Chemistry Department Masaryk University, Brno, Czech Republic. The starting compounds **2-4**, **6** were obtained as described in literature.¹⁸⁻²⁰

Ethyl [4-hydroxy-2-oxo--1-phenyl-1,2-dihydroquinolin-3-yl] carboxylate (4). Condensation of diethyl malonate and isatoic anhydride derivative in the presence of sodium hydride in dry dimethylformamide led to compound **4**.¹⁹ Yield 74% white crystals, mp 188-189 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 14.45 (1H, s, OH); 8.21 (1H, d, *J* 8.0, ArH); 7.58–7.22 (7H, m, ArH); 6.61 (1H, d, *J* 8.0, ArH); 4.28 (2H, q, *J* 6.0, OCH₂); 1.45 (3H, t, *J* 6.0, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.7 (C=O ester); 172.5 (C-OH); 159.7 (C=O amide); 142.3 (C Ar); 137.6 (C Ar); 133.9 (CHAr); 130.1 (CHAr); 129.3 (CHAr); 128.8 (CHAr); 125.3 (CHAr); 122.1 (CHAr); 115.9 (CHAr); 114.7 (C Ar); 98.1 (C Ar); 62.3 (OCH₂); 14.3 (CH₃). Found, %: C, 69.65; H, 4.81; N, 4.49. For C₁₈H₁₅NO₄ (309.1). Calculated, %: C, 69.89; H, 4.89; N, 4.53.

[4-Hydroxy-2-oxo--1-phenyl-1,2-dihydroquinolin-3yl] carbohydrazide (5). To a solution of ster derivative **4** (0.31 g, 1.0 mmol) in ethyl alcohol (15 mL), hydrazine hydrate (0.4 mL, 1.0 mmol) was added. The reaction mixture was refluxed for 4 hours, cooled and the resultant precipitate was filtered off, washed with ethanol and ether then crystallized from aqueous ethanol to yield the hydrazide **5**. 0.18 g, Yield 62% white crystals, mp 209-210 °C. ¹H NMR spectrum, (300 MHz, DMSO-*d*₆), δ, ppm (*J*, Hz): 10.78 (1H, s, NH); 8.15 (1H, d, *J* 8.0, ArH); 7.70–7.52 (5H, m, ArH); 7.38–7.18 (5H, m, ArH); 6.53 (1H, d, *J* 8.0, ArH); 4.86 (2H, bs, NH₂). ¹³C NMR spectrum, (75.0 MHz, DMSO-*d*₆), δ, ppm: 171.7 (C=O ester); 168.4 (C-OH); 161.2 (C=O amide); 141.0 (C Ar); 137.4 (C Ar); 134.2 (CHAr); 130.5 (CHAr); 129.6 (CHAr); 129.4 (CHAr); 124.8 (CHAr); 123.2 (CHAr); 116.3 (CHAr); 115.2 (C Ar). Found, %: C, 64.96; H, 4.38; N, 14.12. For C₁₆H₁₃N₃O₃ (295.1). Calculated, %: C, 65.08; H, 4.44; N, 14.23.

4-Hydroxy-1-phenyl-2-oxo-1,2-dihydro-3-quinoline carboxylic acid (6). To a solution of acetic anhydride (450 mL) at 0 °C was slowly added (very exothermic) concentrated HCl (138 mL, 37%). This yields an approximately 2.8 M solution of HCl in acetic acid with a low water content, and the solution can be kept in a refrigerator for several years. To ethyl 4-hydroxy-1-phenyl-2-oxo-1,2-dihydro-3-quinolinecarboxylate **4** (0.31 g, 1.0 mmol) was added 10 mL of the above solution of 2.8 M HCl in acetic acid, and the mixture was heated for 6 h at 60 °C using a reflux condenser. The reaction mixture was cooled and resultant crystals were filtered off, washed with 2-propanol, and dried in a vacuum to furnish the product 4-hydroxy-1-phenyl-2-oxo-1,2-dihydro-3-quinoline carboxylic acid. White crystals, 0.24g, Yield 87% white crystals, mp 195-196 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 15.16 (1H, s, OH); 14.75 (1H, s, OH); 8.31 (1H, d, *J* 8.0, ArH); 7.68–7.58 (4H, m, ArH); 7.44–7.34 (3H, m, ArH); 6.81 (1H, d, *J* 8.0, ArH). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.3 (C=O ester); 172.2 (C-OH); 165.0 (C=O amide); 140.8 (C Ar); 135.7 (C Ar); 134.7 (CHAr); 130.5 (CHAr); 129.8 (CHAr); 128.7 (CHAr); 125.6 (CHAr); 123.9 (CHAr); 116.8 (CHAr); 115.6 (C Ar); 95.2 (C Ar). Found, %: C, 68.17; H, 3.75; N, 4.87. For C₁₆H₁₁NO₄ (281.1). Calculated, %: C, 68.32; H, 3.94; N, 4.98.

Methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] alkanoates (7a-f). Method A. Amino acid ester hydrochloride (1.2 mmol) and ethyl 1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-3-quinolinecarboxylate **4** (3.7 g, 1.0 mmol) and triethylamine (0.12 mL, 1.2 mmol) were dissolved in 100 mL of dry toluene. The reaction mixture was refluxed and an amount of approximately 60 mL of the volatiles was distilled off at atmospheric pressure for 6 h. using a Dean stark system. After cooling, the reaction mixture was evaporated under reduced pressure and the resultant solid was crystalized from ethanol.

Method B. To a solution of 4-hydroxy-1-phenyl-2-oxo-1,2-dihydro-3-quinoline carboxylic acid **6** (0.28 g, 1.0 mmol) was added CH₂Cl₂ (38 mL), triethylamine (0.20 mL, 2.0 mmol), and *N*-ethylaniline (0.2 mL, 1.2 mmol).

The mixture was stirred under nitrogen and cooled to 0 °C, and a solution of thionyl chloride (0.2 mL, 1.5 mmol) in CH₂Cl₂ (10 mL) was added during 30 min. The stirring was continued at 0 °C for 4 h and then at room temperature for 30 min. The reaction mixture was diluted with CHCl₃ and quickly washed with cold 1 M H₂SO₄. The organic phase was dried over sodium sulfate and then evaporated. The oily residue was then purified using flash column chromatography using pet. ether : ethyl acetate 3:1 eluent to give the amino acid ester derivatives **7a-f**:

Methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] acetate (7a). Method A: 0.31 g, Yield 88%, Method B: 0.042 g, Yield 12%. white crystals, mp 194-195 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.67 (1H, s, OH); 10.55 (1H, bs, NH); 8.26 (1H, d, *J* 9.0, ArH); 7.64–7.29 (7H, m, ArH); 6.69 (1H, d, *J* 8.0, ArH); 4.20 (2H, d, *J* 6.0, CH₂); 3.78 (3H, s, OCH₃). ¹³C NMR spectrum, δ, ppm: 172.6 (C=O ester); 171.4 (C-OH); 169.4 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.1 (C Ar); 133.5 (CHAr); 130.3 (CHAr); 129.1 (CHAr); 129.0 (CHAr); 125.2 (CHAr); 122.7 (CHAr); 116.1 (CHAr); 115.8 (C Ar); 96.9 (C Ar); 52.4 (OCH₃); 40.9 (CH₂). Found, %: C, 64.57; H, 4.42; N, 7.81. For C₁₉H₁₆N₂O₅ (352.1). Calculated, %: C, 64.77; H, 4.58; N, 7.95.

Methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl) carbonylamino]propanoate (7b). Method A: 0.24 g, Yield 65%, Method B. 0.033 g, Yield 8%. white crystals, mp 150-151 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.81 (1H, s, OH); 10.48 (1H, d, *J* 6.0, NH); 8.24 (1H, d, *J* 8.0, ArH); 7.62–7.28 (7H, m, ArH); 6.65 (1H, d, *J* 8.0, ArH); 4.74–4.67 (1H, m, CH); 3.76 (3H, s, OCH₃); 1.51 (3H, d, *J* 6.0, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.8 (C=O ester); 172.6 (C-OH); 171.8 (C=O amide); 170.7 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.1 (C Ar); 133.4 (CHAr); 130.3 (CHAr); 129.2 (CHAr); 129.1 (CHAr); 129.0 (CHAr); 125.2 (CHAr); 122.7 (CHAr); 116.1 (CHAr); 115.9 (C Ar); 96.8 (C Ar); 52.4 (OCH₃); 48.0 (CH); 18.3 (CH₃). Found, %: C, 65.54; H, 4.84; N, 7.48. For C₂₀H₁₈N₂O₅ (366.1). Calculated, %: C, 65.57; H, 4.95; N, 7.65.

Methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl) carbonylamino] 4-methyl-pentanoate (7c). Method A: 0.31 g, Yield 75%, Method B, 0.037 g, Yield 9%. white crystals, mp 120-121 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.48 (1H, s, OH); 10.14 (1H, bs, NH); 8.25 (1H, d, *J* 8.0, ArH); 7.63–7.28 (7H, m, ArH); 6.65 (1H, d, *J* 8.0, ArH); 3.66 (3H, s, OCH₃); 3.42 (2H, q, *J* 6.0, CH₂); 2.32 (2H, t, *J* 6.0, CH₂); 1.69-1.41 (6H, m, 2CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.9 (C=O ester); 173.0 (C-OH); 172.9 (C=O amide); 171.0 (C=O amide); 163.1 (C=O amide); 140.8 (C Ar); 137.2 (C Ar); 133.2 (CHAr); 130.3 (CHAr); 129.1 (CHAr); 129.0 (CHAr); 125.2 (CHAr); 122.6 (CHAr); 116.2 (CHAr); 116.0 (C Ar); 96.7 (C Ar); 51.4 (OCH₃); 38.9 (C-Leu); 33.9 (CH₂-Leu); 29.0 (CH₂-Leu); 26.5 (CH₃); 24.6 (CH₃). Found, %: C, 67.59; H, 5.84; N, 6.77. For C₂₃H₂₄N₂O₅ (408.2). Calculated, %: C, 67.63; H, 5.92; N, 6.86.

Methyl 3-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl) carbonylamino]propanoate (7d). Method A: 0.33 g, Yield 89%, Method B: 0.066 g, Yield 18%. white crystals, mp 190-191 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.20 (1H, s, OH); 10.31 (1H, bs, NH); 8.26 (1H, d, *J* 8.0, ArH); 7.64–7.28 (7H, m, ArH); 6.66 (1H, d, *J* 8.0, ArH); 3.77–3.69 (3H, m, CH₂, OCH₃); 2.67 (2H, t, *J* 6.0, CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.9 (C=O ester); 171.8 (C-OH); 171.3 (C=O amide); 163.0 (C=O amide); 140.9 (C Ar); 137.2 (C Ar); 133.3 (CHAr); 130.3 (CHAr); 129.1 (CHAr); 129.0 (CHAr); 125.2 (CHAr); 122.6 (CHAr); 116.0 (CHAr); 96.8 (C Ar); 51.8 (OCH₃); 34.9 (CH₂); 33.9 (CH₂). Found, %: C, 65.40; H, 4.86; N, 7.59. For C₂₀H₁₈N₂O₅ (366.1). Calculated, %: C, 65.57; H, 4.95; N, 7.65.

Methyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] 2-phenyl acetate (7e). Method A: 0.40 g, Yield 93%. Method B: 0.03 g, Yield 7%. white crystals, mp 190-191 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.64 (1H, s, OH); 10.95 (1H, d, *J* 6.0, NH); 8.25 (1H, d, *J* 8.0, ArH); 7.63–7.28 (13H, m, ArH, NH); 6.64 (1H, d, *J* 8.0, ArH); 5.74 (1H, d, *J* 6.0, CH); 3.77 (3H, s, OCH₃). ¹³C NMR spectrum, (75.0

MHz, CDCl₃), δ , ppm: 172.7 (C=O ester); 170.6 (C-OH); 170.5 (C=O amide); 162.8 (C=O amide); 141.0 (C Ar); 135.7 (C Ar); 133.5 (CHAr); 130.4 (CHAr); 129.3 (CHAr); 129.2 (CHAr); 129.1 (CHAr); 129.0 (CHAr); 128.7 (CHAr); 127.6 (CHAr); 125.2 (CHAr); 122.6 (CHAr); 116.1 (CHAr); 115.8 (C Ar); 97.0 (C Ar); 56.9 (CH); 52.8 (OCH₃). Found, %: C, 69.97; H, 4.66; N, 6.37. for C₂₅H₂₀N₂O₅ (428.1). Calculated, %: C, 70.08; H, 4.71; N, 6.54.

Dimethyl 2-[(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl) carbonylamino] 1,5-pentandioate (7f).

Method A: 0.32g, Yield 74%, Method B: 0.026g, Yield 6%, Method B. white crystals, mp 150-151 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ , ppm (*J*, Hz): 16.65 (1H, s, OH); 10.54 (1H, d, *J* 6.0, NH); 8.18 (1H, d, *J* 8.0, ArH); 7.60–7.26 (7H, m, ArH); 6.61 (1H, d, d, *J* 8.0, ArH); 4.78–4.76 (1H, m, CH); 3.80–3.56 (8H, m, CH₂, 2OCH₃); 2.43 (2H, t, *J* 6.0, CH₂). ¹³C NMR spectrum, δ , ppm: 172.7 (C=O ester); 172.6 (C=O ester); 171.3 (C-OH); 171.0 (C=O amide); 162.8 (C=O amide); 141.0 (C Ar); 137.1 (C Ar); 133.5 (CHAr); 130.3 (CHAr); 129.2 (CHAr); 129.0 (CHAr); 125.1 (CHAr); 122.7 (CHAr); 116.1 (CHAr); 115.7 (C Ar); 96.7 (C Ar); 52.5 (OCH₃); 51.7 (OCH₃); 51.4 (CH); 30.1 (CH₂); 27.2 (CH₂). Found, %: C, 62.84; H, 4.87; N, 6.28. For C₂₃H₂₂N₂O₇ (438.1). Calculated, %: C, 63.01; H, 5.06; N, 6.39.

2-[2-(1,2-Dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] alkanehydrazides 8a-d. General method.

To a solution of methyl-2-[2-(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carboxamido] alkanoate **7a-d** (1.0 mmol) in absolute ethyl alcohol (30 mL), hydrazine hydrate (0.24 mL, 5 mmol) was added. The reaction mixture was refluxed for 4 hours, afterwards it was left overnight at room temperature. The formed precipitate was filtered off, washed with aqueous ethanol and ether then crystallized from ethanol to yield the hydrazide.

2-[(1,2-Dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] ethanhydrazide (8a). 0.27 g, Yield 78% white crystals, mp 270-271 °C. ¹H NMR spectrum, (300 MHz, DMSO-*d*₆), δ , ppm (*J*, Hz): 10.38 (1H, bs, NH); 9.38 (1H, bs, NH); 8.13 (1H, d, *J* 8.0, ArH); 7.65–7.60 (4H, m, ArH); 7.38–7.36 (3H, m, ArH); 6.57 (1H, d, *J* 8.0, ArH); 4.48 (3H, bs, NH₂); 4.15 (2H, d, *J* 6.0, CH₂). ¹³C NMR spectrum, (75.0 MHz, DMSO-*d*₆), δ , ppm: 172.3 (C=O ester); 171.0 (C-OH); 167.5 (C=O amide); 162.1 (C=O amide); 141.2 (C Ar); 137.5 (C Ar); 134.4 (CHAr); 130.5 (CHAr); 129.7 (CHAr); 129.4 (CHAr); 125.0 (CHAr); 123.1 (CHAr); 116.4 (CHAr); 115.4 (C Ar); 96.8 (C Ar); 41.2 (CH₂). Found, %: C, 61.24; H, 4.48; N, 15.73. for C₁₈H₁₆N₄O₄ (352.1). Calculated, %: C, 61.36; H, 4.58; N, 15.90.

2-[(1,2-Dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] propan-hydrazide (8b). 0.24 g, Yield 65% white crystals, mp 230-231 °C. ¹H NMR spectrum, (300 MHz, DMSO-*d*₆), δ , ppm (*J*, Hz): 10.44 (1H, bs, NH); 9.41 (1H, bs, NH); 8.12 (1H, d, *J* 8.0, ArH); 7.63–7.55 (4H, m, ArH); 7.35–7.28 (3H, m, ArH); 6.51 (1H, d, *J* 8.0, ArH); 5.25 (3H, bs, NH₂); 4.53–4.46 (1H, m, CH); 1.31 (3H, d, *J* 6.0, CH₃). ¹³C NMR spectrum, (75.0 MHz, DMSO-*d*₆), δ , ppm: 173.0 (C=O ester); 171.2 (C-OH); 169.9 (C=O amide); 162.9 (C=O amide); 141.2 (C Ar); 138.0 (C Ar); 133.6 (CHAr); 130.4 (CHAr); 129.9 (CHAr); 129.1 (CHAr); 125.2 (CHAr); 122.6 (CHAr); 116.0 (CHAr); 115.6 (C Ar); 97.3 (C Ar); 47.3 (CH); 19.4 (CH₃). Found, %: C, 62.12; H, 4.87; N, 15.17. For C₁₉H₁₈N₄O₄ (366.1). Calculated, %: C, 62.29; H, 4.95; N, 15.29.

2-[(1,2-Dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] 4-methyl pentanhydrazide (8c).

0.31g, Yield 76% white crystals, mp 170-171 °C. ¹H NMR spectrum, (300 MHz, DMSO-*d*₆), δ , ppm (*J*, Hz): 10.15 (1H, bs, NH); 8.84 (1H, bs, NH); 8.14 (1H, d, *J* 8.0, ArH); 7.64–7.57 (4H, m, ArH); 7.39–7.36 (3H, m, ArH); 6.57 (1H, d, *J* 8.0, ArH); 3.54 (2H, q, *J* 6.0, CH₂); 2.01 (2H, t, *J* 6.0, CH₂); 1.54-1.25 (6H, m, 2CH₃). ¹³C NMR spectrum, (75.0 MHz, DMSO-*d*₆), δ , ppm: 172.6 (C=O ester); 171.9 (C-OH); 170.9 (C=O amide); 163.1 (C=O amide); 141.1 (C Ar); 137.5 (C Ar); 134.4 (CHAr); 130.5 (CHAr); 129.7 (CHAr); 125.0 (CHAr); 123.1 (CHAr); 116.4 (CHAr); 96.8 (C Ar); 38.9 (C-Leu); 33.7 (CH₂-Leu); 28.9 (CH₂-Leu); 26.5 (CH₃); 25.3 (CH₃). Found, %: C, 64.57; H, 5.85; N, 13.61. For C₂₂H₂₄N₄O₄ (408.2). Calculated, %: C, 64.69; H, 5.92; N, 13.72.

3-[(1,2-Dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino] propanhydrazide (8d). 0.31g, Yield 84% white crystals, mp 245-246 °C. ¹H NMR spectrum, (300 MHz, DMSO-*d*₆), δ, ppm (*J*, Hz): 10.24 (1H, bs, NH); 9.04 (1H, bs, NH); 8.14 (1H, d, *J* 8.0, ArH); 7.66–7.57 (4H, m, ArH); 7.38–7.35 (3H, m, ArH); 6.56 (1H, d, *J* 8.0, ArH); 3.57 (2H, q, *J* 6.0, CH₂); 2.36 (2H, t, *J* 6.0, CH₂). ¹³C NMR spectrum, (75.0 MHz, DMSO-*d*₆), δ, ppm: 172.6 (C=O ester); 171.0 (C-OH); 170.0 (C=O amide); 163.7 (C=O amide); 141.2 (C Ar); 137.5 (C Ar); 134.4 (CHAr); 130.5 (CHAr); 129.7 (CHAr); 129.4 (CHAr); 125.0 (CHAr); 123.0 (CHAr); 116.2 (CHAr); 115.6 (CHAr); 96.5 (C Ar); 35.5 (CH₂); 33.1 (CH₂). Found, %: C, 62.11; H, 4.73; N, 15.06. For C₁₉H₁₈N₄O₄ (366.1). Calculated, %: C, 62.29; H, 4.95; N, 15.29.

Methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)alkan-amido] alkanoate 10-13 (a-f). General method. To a cold solution (-5 °C) of quinoline hydrazide **8a-d** (1.0 mmol) in AcOH (6 mL), 1 N HCl (3 mL), and water (25 mL) was added a solution of NaNO₂ (0.87 g, 1.0 mmol) in cold water (3 mL). After stirring at -5 °C for 15 min to afford a yellowish syrup. The reaction mixture was extracted with cold ethyl acetate (30 mL), washed with cold 3% NaHCO₃, H₂O and finally dried (Na₂SO₄) to give the *in situ* generated ethyl acetate solution of azide **9a-d**. A prepared cold solution of amino acid methyl ester hydrochloride (1.0 mmol) in ethyl acetate (20 mL) and triethylamine (20 mL, 1.0 mmol) was added to the azide solution **9a-d**. The mixture was kept at -5 °C for 24 h, then at 25 °C for another 24 h, followed by washing with 3% solution of NaHCO₃ and dried (Na₂SO₄). The solution was evaporated to dryness, and the residue was recrystallized from petroleum ether/ ethyl acetate to give the desired 2-[2-(1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carboxy] dipeptide ester derivatives **10-13 (a-f)**.

Methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-acetamido] acetate (10a). 0.29 g, Yield 72% white crystals, mp 205-206 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.54 (1H, s, OH); 10.55 (1H, bs, NH); 8.25 (1H, d, *J* 9.0, ArH); 7.63–7.28 (7H, m, ArH); 6.71–6.66 (2H, m, ArH, NH); 4.17 (4H, d, *J* 6.0, 2CH₂); 3.75 (3H, s, OCH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.7 (C=O ester); 171.8 (C-OH); 170.0 (C=O amide); 168.6 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.7 (CHAr); 130.3 (CHAr); 129.2 (CHAr); 129.0 (CHAr); 128.7 (CHAr); 125.3 (CHAr); 122.8 (CHAr); 116.2 (CHAr); 115.7 (C Ar); 96.8 (C Ar); 52.3 (OCH₃); 45.0 (CH₂); 41.3 (CH₂). Found, %: C, 61.49; H, 4.47; N, 9.98. For C₂₁H₁₉N₃O₆ (409.1). Calculated, %: C, 61.61; H, 4.68; N, 10.26.

Methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-acetamido] propanoate (10b). 0.21 g, Yield 49% white crystals, mp 208-209 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.57 (1H, s, OH); 10.62 (1H, t, *J* 6.0, NH); 8.26 (1H, d, *J* 9.0, ArH); 7.64–7.28 (7H, m, ArH); 6.69 (2H, d, *J* 9.0, ArH, NH); 4.67–4.58 (1H, m, CH); 4.21–4.01 (2H, m, CH₂); 3.75 (3H, s, OCH₃); 1.42 (3H, d, *J* 6.0, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.2 (C=O ester); 172.7 (C-OH); 171.8 (C=O amide); 167.9 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.6 (CHAr); 130.4 (CHAr); 129.3 (CHAr); 125.3 (CHAr); 122.8 (CHAr); 116.1 (CHAr); 115.8 (C Ar); 96.8 (C Ar); 52.5 (OCH₃); 48.1 (CH); 43.1 (CH₂); 18.3 (CH₃). Found, %: C, 62.14; H, 4.74; N, 9.69. For C₂₂H₂₁N₃O₆ (423.1). Calculated, %: C, 62.41; H, 5.00; N, 9.92.

Methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-acetamido] 4-methylpentanoate (10c). 0.34 g, Yield 73% white crystals, mp 140-141°C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.53 (1H, s, OH); 10.59 (1H, t, *J* 6.0, NH); 8.28 (1H, d, *J* 9.0, ArH); 7.64–7.28 (13H, m, ArH, NH); 6.70 (1H, d, *J* 9.0, ArH); 6.19 (1H, bs, NH); 4.70 (2H, d, *J* 6.0, ArH); 3.66 (3H, s, OCH₃); 3.31–3.24 (2H, m, CH₂); 2.33–2.28 (2H, m, CH₂); 1.68–1.34 (6H, m, 2CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 174.0 (C=O ester); 172.7 (C-OH); 171.8 (C=O amide); 168.3 (C=O amide); 163.0 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.7 (CHAr); 129.3 (CHAr); 128.9 (CHAr); 125.5 (CHAr); 122.8 (CHAr); 116.1 (CHAr); 115.8 (C Ar); 96.8 (C Ar);

51.4 (OCH₃); 43.3 (CH₂); 39.3 (CH₂); 33.8 (CH₂); 29.2 (CH₂); 26.3 (CH₃); 24.5 (CH₃). Found, %: C, 64.28; H, 5.74; N, 8.83. For C₂₅H₂₇N₃O₆ (465.2). Calculated, %: C, 64.50; H, 5.85; N, 9.03.

Methyl 3-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-acetamido] propanoate (10d). 0.26 g, Yield 62% white crystals, mp 170-171 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.56 (1H, s, OH); 10.51 (1H, t, *J* 6.0, NH); 8.28 (1H, d, *J* 9.0, ArH); 7.66–7.28 (7H, m, ArH); 6.71–6.67 (2H, m, ArH, NH); 4.11 (2H, d, *J* 6.0, CH₂), 3.75 (3H, s, OCH₃); 3.55 (2H, q, *J* 6.0, CH₂); 2.55 (2H, t, *J* 6.0, CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.7 (C=O ester); 172.7 (C-OH); 171.8 (C=O amide); 168.4 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.7 (CHAr); 130.3 (CHAr); 130.2 (CHAr); 129.2 (CHAr); 129.0 (CHAr); 128.9 (CHAr); 125.2 (CHAr); 122.8 (CHAr); 116.2 (CHAr); 115.8 (C Ar); 96.8 (C Ar); 51.7 (OCH₃); 43.2 (CH₂); 34.9 (CH₂); 33.7 (CH₂). Found, %: C, 62.28; H, 4.75; N, 9.75. For C₂₂H₂₁N₃O₆ (423.1). Calculated, %: C, 62.41; H, 5.00; N, 9.92.

Methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-acetamido] 2-phenyl acetate (10e). 0.40 g, Yield 83% white crystals, mp 185-186 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.56 (1H, s, OH); 10.63 (1H, d, *J* 9.0, NH); 8.27 (1H, d, *J* 9.0, ArH); 7.37–7.28 (13H, m, ArH, NH); 6.69 (1H, d, *J* 9.0, ArH); 5.61 (1H, d, *J* 6.0, CH); 4.14 (2H, d, *J* 6.0, CH₂); 3.74 (3H, s, OCH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.7 (C=O ester); 171.9 (C-OH); 171.0 (C=O amide); 167.7 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 136.2 (C Ar); 133.6 (CHAr); 130.3 (CHAr); 129.2 (CHAr); 129.0 (CHAr); 128.9 (CHAr); 128.5 (CHAr); 127.3 (CHAr); 125.3 (CHAr); 122.8 (CHAr); 116.2 (CHAr); 115.8 (C Ar); 96.7 (C Ar); 56.5 (CH); 52.8 (OCH₃); 43.2 (CH). Found, %: C, 66.68; H, 4.64; N, 8.38. for C₂₇H₂₃N₃O₆ (485.2). Calculated, %: C, 66.80; H, 4.78; N, 8.66.

Dimethyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-acetamido] 1,5-pentandioate (10f). 0.33 g, Yield 66% white crystals, mp 140-141 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.58 (1H, s, OH); 10.53 (1H, t, *J* 6.0, NH); 8.28 (1H, d, *J* 9.0, ArH); 7.68–7.28 (7H, m, ArH); 7.01 (1H, d, *J* 6.0, NH); 6.63 (1H, d, d, *J* 9.0, ArH); 4.11 (2H, d, *J* 6.0, CH₂), 3.76 (3H, s, OCH₃); 3.67 (3H, s, OCH₃); 2.44–2.01 (4H, m, 2CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.2 (C=O ester); 172.6 (C=O ester); 172.1 (C-OH); 171.7 (C=O amide); 168.5 (C=O amide); 162.8 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.2 (CHAr); 130.2 (CHAr); 129.2 (CHAr); 129.1 (CHAr); 125.1 (CHAr); 122.7 (CHAr); 116.1 (CHAr); 115.7 (C Ar); 96.8 (C Ar); 52.5 (OCH₃); 51.8 (OCH₃); 51.7 (CH); 43.0 (CH₂); 30.0 (CH₂); 27.1 (CH₂). Found, %: C, 60.49; H, 4.83; N, 8.23. For C₂₅H₂₅N₃O₈ (495.2). Calculated, %: C, 60.60; H, 5.09; N, 8.48.

Methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] acetate (11a). 0.31 g, Yield 73% white crystals, mp 194-195 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.59 (1H, s, OH); 10.48 (1H, d, *J* 9.0, NH); 8.25 (1H, d, *J* 9.0, ArH); 7.64–7.28 (7H, m, ArH); 6.81 (1H, bs, NH); 6.66 (1H, d, *J* 9.0, ArH); 4.72–4.61 (1H, m, CH); 4.07 (2H, s, CH₂); 3.75 (3H, s, OCH₃); 1.50 (3H, d, *J* 6.0, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.7 (C=O ester); 171.8 (C-OH); 171.2 (C=O amide); 170.1 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.6 (CHAr); 130.4 (CHAr); 129.3 (CHAr); 129.0 (CHAr); 128.9 (CHAr); 125.2 (CHAr); 122.8 (CHAr); 116.1 (CHAr); 115.8 (C Ar); 96.9 (C Ar); 52.3 (OCH₃); 49.0 (CH); 41.3 (CH₂); 13.3 (CH₃). Found, %: C, 62.23; H, 4.92; N, 9.67. For C₂₂H₂₁N₃O₆ (423.1). Calculated, %: C, 62.41; H, 5.00; N, 9.92.

Methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] propanoate (11b). 0.18 g, Yield 41% white crystals, mp 160-161 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.65 (1H, s, OH); 10.46 (1H, d, *J* 6.0, NH); 8.24 (1H, d, *J* 9.0, ArH); 7.65–7.28 (7H, m, ArH); 6.76 (1H, d, *J* 6.0, NH); 6.67 (1H, d, *J* 9.0, ArH); 4.66–4.59 (2H, m, 2CH); 3.73 (3H, s, OCH₃); 1.49 (6H, d, *J* 6.0, 2CH₃). ¹³C NMR spectrum, δ, ppm: 173.1 (C=O ester); 172.8 (C-OH); 171.2 (C=O amide); 171.0 (C=O amide); 163.0

(C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.6 (CHAR); 130.4 (CHAR); 129.3 (CHAR); 129.0 (CHAR); 128.9 (CHAR); 125.2 (CHAR); 122.8 (CHAR); 116.1 (CHAR); 115.8 (C Ar); 96.7 (C Ar); 52.4 (OCH₃); 49.1 (CH); 48.2 (CH); 18.3 (CH₃); 17.3 (CH₃). Found, %: C, 63.03; H, 5.28; N, 9.49. For C₂₃H₂₃N₃O₆ (437.2). Calculated, %: C, 63.15; H, 5.30; N, 9.61.

Methyl 2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] 4-methylpentanoate (11c). 0.31 g, Yield 64% white crystals, mp 140-141 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.66 (1H, s, OH); 10.43 (1H, d, *J* 9.0, NH); 8.26 (1H, d, *J* 9.0, ArH); 7.65–7.28 (13H, m, ArH, NH); 6.67 (1H, d, *J* 9.0, ArH); 6.29 (1H, bs, NH); 4.61–4.59 (1H, m, CH); 3.65 (3H, s, OCH₃); 3.30–3.22 (2H, m, CH₂); 2.33–3.28 (2H, m, CH₂); 1.67–1.48 (9H, m, 3CH₃). ¹³C NMR spectrum, δ, ppm: 174.0 (C=O ester); 172.8 (C-OH); 171.4 (C=O amide); 171.1 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.6 (CHAR); 129.3 (CHAR); 128.9 (CHAR); 125.2 (CHAR); 116.2 (CHAR); 115.8 (C Ar); 94.7 (C Ar); 51.4 (OCH₃); 49.3 (CH); 39.3 (CH₂); 33.9 (CH₂); 29.2 (CH₂); 26.3 (CH₃); 24.5 (CH₃); 17.4 (CH₃). Found, %: C, 64.83; H, 5.96; N, 8.54. For C₂₆H₂₉N₃O₆ (479.2). Calculated, %: C, 65.12; H, 6.10; N, 8.76.

Methyl-3-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] propanoate (11d). 0.34 g, Yield 78% white crystals, mp 199-200 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.66 (1H, s, OH); 10.43 (1H, d, *J* 9.0, NH); 8.26 (1H, d, *J* 9.0, ArH); 7.65–7.28 (7H, m, ArH); 6.71–6.66 (2H, m, ArH, NH); 4.60–4.51 (1H, m, CH); 3.68 (3H, s, OCH₃); 3.59–3.55 (2H, m, CH₂); 2.55 (2H, t, *J* 6.0, CH₂); 1.47 (3H, d, *J* 6.0, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.7 (C=O ester); 172.8 (C-OH); 171.6 (C=O amide); 171.1 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.6 (CHAR); 130.4 (CHAR); 129.3 (CHAR); 129.0 (CHAR); 128.9 (CHAR); 125.2 (CHAR); 122.8 (CHAR); 116.2 (CHAR); 115.8 (C Ar); 96.7 (C Ar); 51.7 (OCH₃); 49.4 (CH); 35.6 (CH₂); 33.7 (CH₂); 17.4 (CH₃). Found, %: C, 63.00; H, 5.46; N, 9.55. For C₂₃H₂₃N₃O₆ (437.2). Calculated, %: C, 63.15; H, 5.30; N, 9.61.

Methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] 2-phenyl acetate (11e). 0.37 g, Yield 74% white crystals, mp 205-206 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.65 (1H, s, OH); 10.47 (1H, d, *J* 9.0, NH); 8.27 (1H, d, *J* 9.0, ArH); 7.38–7.28 (13H, m, ArH, NH); 6.67 (1H, d, *J* 9.0, ArH); 5.58 (1H, d, *J* 5.7, CH); 4.72–4.63 (1H, m, CH); 3.73 (3H, s, OCH₃); 1.47 (1H, d, *J* 9.0, CH). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.6 (C=O ester); 171.3 (C-OH); 171.2 (C=O amide); 171.0 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 136.4 (C Ar); 136.3 (CHAR); 133.6 (CHAR); 130.4 (CHAR); 129.3 (CHAR); 129.0 (CHAR); 128.6 (CHAR); 128.4 (CHAR); 127.3 (CHAR); 127.2 (CHAR); 125.3 (CHAR); 122.8 (CHAR); 116.1 (CHAR); 115.8 (C Ar); 96.7 (C Ar); 56.6 (CH); 52.8 (OCH₃); 49.1 (CH); 17.2 (CH₃). Found, %: C, 67.33; H, 5.04; N, 8.41. for C₂₈H₂₅N₃O₆ (499.2). Calculated, %: C, 67.16; H, 5.01; N, 8.27.

Methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] 1,5-pentandioate (11f). 0.24 g, Yield 48% white crystals, mp 180-181 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 16.61 (1H, s, OH); 10.46 (1H, d, *J* 9.0, NH); 8.26 (1H, d, *J* 9.0, ArH); 7.65–7.28 (7H, m, ArH); 6.68 (1H, d, *J* 6.0, NH); 6.65 (1H, d, *J* 9.0, ArH); 4.67–4.57 (1H, m, CH); 3.79 (3H, s, OCH₃); 3.73 (3H, s, OCH₃); 2.48–1.97 (4H, m, 2CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), (75.0 MHz, CDCl₃), δ, ppm: 173.2 (C=O ester); 172.7 (C=O ester); 172.1 (C-OH); 171.5 (C=O amide); 171.2 (C=O amide); 162.9 (C=O amide); 141.0 (C Ar); 137.0 (C Ar); 133.6 (CHAR); 130.4 (CHAR); 129.3 (CHAR); 129.0 (CHAR); 128.9 (CHAR); 125.2 (CHAR); 122.8 (CHAR); 116.1 (CHAR); 115.8 (C Ar); 96.8 (C Ar); 52.5 (OCH₃); 51.7 (OCH₃); 51.0 (CH); 48.3 (CH); 28.9 (CH₂); 27.3 (CH₂); 17.3 (CH₃). Found, %: C, 61.07; H, 5.09; N, 8.12. For C₂₆H₂₇N₃O₈ (509.2). Calculated, %: C, 61.29; H, 5.34; N, 8.25.

Methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-4-methyl-pentanamido] acetate (12a). 0.32 g, Yield 68% white crystals, mp 134-135 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.53 (1H, s, OH); 10.12 (1H, bs, NH); 8.23 (1H, d, *J* 8.0, ArH); 7.62–7.28 (7H, m, ArH); 6.64 (1H, d, *J* 8.0,

ArH); 6.12 (1H, bs, NH); 3.99 (2H, q, *J* 6.0, CH₂); 3.73 (3H, s, OCH₃); 3.41 (2H, d, *J* 6.0, CH₂); 2.23 (2H, t, *J* 6.0, CH₂); 1.68-1.42 (6H, m, 2CH₃). ¹³C NMR spectrum, δ, ppm: 173.1 (C=O ester); 173.0 (C-OH); 171.0 (C=O amide); 170.5 (C=O amide); 163.1 (C=O amide); 140.8 (C Ar); 137.2 (C Ar); 133.2 (CHAR); 130.3 (CHAR); 129.1 (CHAR); 129.0 (CHAR); 123.2 (CHAR); 122.6 (CHAR); 116.2 (CHAR); 116.0 (C Ar); 96.7 (C Ar); 52.2 (OCH₃); 41.1 (CH₂); 38.9 (C-Leu); 36.0 (CH₂-Leu); 28.9 (CH₂-Leu); 26.6 (CH₃); 25.1 (CH₃). Found, %: C, 64.32; H, 5.67; N, 8.73. For C₂₅H₂₇N₃O₆ (465.2). Calculated, %: C, 64.50; H, 5.85; N, 9.03.

Methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-4-methylpentanamido] propanoate (12b). 0.27 g, Yield 56% white crystals, mp 83-84 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.49 (1H, s, OH); 10.41 (1H, bs, NH); 8.26 (1H, d, *J* 8.0, ArH); 7.64-7.28 (7H, m, ArH); 6.66 (1H, d, *J* 8.0, ArH); 6.05 (1H, bs, NH); 4.65-4.55 (1H, m, CH); 3.75 (3H, s, OCH₃); 3.44 (2H, q, *J* 6.0, CH₂); 2.22 (2H, t, *J* 6.0, CH₂); 1.71-1.39 (9H, m, 3CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.6 (C=O ester); 173.0 (C-OH); 172.3 (C=O amide); 171.0 (C=O amide); 163.1 (C=O amide); 140.8 (C Ar); 137.2 (C Ar); 133.2 (CHAR); 130.3 (CHAR); 129.1 (CHAR); 129.0 (CHAR); 125.2 (CHAR); 122.6 (CHAR); 116.2 (CHAR); 116.0 (C Ar); 96.7 (C Ar); 52.4 (OCH₃); 47.9 (CH); 38.9 (C-Leu); 36.3 (CH₂-Leu); 29.0 (CH₂-Leu); 26.6 (CH₃-Leu); 25.1 (CH₃-Leu); 18.5 (CH₃). Found, %: C, 64.86; H, 5.93; N, 8.54. For C₂₆H₂₉N₃O₆ (479.2). Calculated, %: C, 65.12; H, 6.10; N, 8.76.

Methyl-3-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-4-methylpentanamido] propanoate (12d). 0.37 g, Yield 78% white crystals, mp 110-111 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.47 (1H, s, OH); 10.13 (1H, bs, NH); 8.25 (1H, d, *J* 8.0, ArH); 7.63-7.28 (7H, m, ArH); 6.65 (1H, d, *J* 8.0, ArH); 6.11 (1H, bs, NH); 3.70 (3H, s, CH₂, OCH₃); 3.53-3.38 (4H, m, 2CH₂); 2.53 (2H, t, *J* 6.0, CH₂); 2.16 (2H, t, *J* 6.0, CH₂); 1.68-1.36 (6H, m, 2CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.1 (C=O ester); 173.0 (C-OH); 172.8 (C=O amide); 171.0 (C=O amide); 163.1 (C=O amide); 140.8 (C Ar); 137.2 (C Ar); 133.2 (CHAR); 130.3 (CHAR); 129.1 (CHAR); 129.0 (CHAR); 125.2 (CHAR); 122.6 (CHAR); 116.2 (CHAR); 116.0 (C Ar); 96.7 (C Ar); 51.8 (OCH₃); 38.9 (C-Leu); 36.5 (CH₂-Leu); 34.8 (CH₂); 33.9 (CH₂); 29.0 (CH₂-Leu); 26.6 (CH₃); 25.2 (CH₃). Found, %: C, 64.81; H, 5.93; N, 8.57. For C₂₆H₂₉N₃O₆ (479.2). Calculated, %: C, 65.12; H, 6.10; N, 8.76.

Methyl-2-[2-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-4-methylpentanamido] 2-phenylacetate (12e). 0.45g, Yield 84% white crystals, mp 118-119 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.51 (1H, s, OH); 10.15 (1H, bs, NH); 8.21 (1H, d, *J* 8.0, ArH); 7.60-7.23 (12H, m, ArH); 6.73 (1H, bs, NH); 6.63 (1H, d, *J* 8.0, ArH); 5.57 (1H, d, *J* 6.0, CH); 3.68 (3H, s, OCH₃); 3.43 (2H, q, *J* 6.0, CH₂); 2.24 (2H, t, *J* 6.0, CH₂); 1.69-1.41 (6H, m, 2CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.0 (C=O ester); 172.4 (C-OH); 171.5 (C=O amide); 170.9 (C=O amide); 163.0 (C=O amide); 140.8 (C Ar); 137.2 (C Ar); 136.6 (C Ar); 133.2 (CHAR); 130.3 (CHAR); 129.1 (CHAR); 128.9 (CHAR); 128.4 (CHAR); 127.4 (CHAR); 125.1 (CHAR); 122.6 (CHAR); 116.2 (CHAR); 116.0 (C Ar); 96.6 (C Ar); 56.4 (OCH₃); 52.6 (OCH₃); 38.9 (C-Leu); 35.9 (CH₂-Leu); 29.0 (CH₂-Leu); 26.6 (CH₃); 25.07 (CH₃). Found, %: C, 68.48; H, 5.54; N, 7.62. for C₃₁H₃₁N₃O₆ (541.2). Calculated, %: C, 68.75; H, 5.77; N, 7.76.

Methyl 2-[3-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] acetate (13a). 0.28 g, Yield 67% white crystals, mp 187-188 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.10 (1H, s, OH); 10.53 (1H, t, *J* 6.0, NH); 8.26 (1H, d, *J* 8.0, ArH); 7.63-7.28 (7H, m, ArH); 6.66 (1H, d, *J* 8.0, ArH); 6.26 (1H, bs, NH); 4.06 (2H, d, *J* 6.0, CH₂), 3.79-3.70 (5H, m, CH₂, OCH₃); 2.60 (2H, t, *J* 6.0, CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.8 (C=O ester); 171.4 (C-OH); 170.6 (C=O amide); 170.3 (C=O amide); 162.9 (C=O amide); 140.9 (C Ar); 137.2 (C Ar); 133.3 (CHAR); 130.3 (CHAR); 129.1 (CHAR); 129.0 (CHAR); 125.2 (CHAR); 122.6 (CHAR); 116.1 (CHAR); 115.9 (C Ar); 96.8 (C Ar); 52.3 (OCH₃); 41.3 (CH₂); 35.9 (CH₂); 35.3 (CH₂). Found, %: C, 62.12; H, 4.83; N, 9.62. For C₂₂H₂₁N₃O₆ (423.1). Calculated, %: C, 62.41; H, 5.00; N, 9.92.

Methyl 2-[3-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido]propanoate (13b). 0.27 g, Yield 63% white crystals, mp 130-131 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.2 (1H, s, OH); 10.35 (1H, t, *J* 6.0, NH); 8.20 (1H, d, *J* 8.0, ArH); 7.60–7.25 (7H, m, ArH); 6.63 (1H, d, *J* 8.0, ArH); 6.47 (1H, d, *J* 6.0, NH); 4.63–4.53 (1H, m, CH); 3.75–3.69 (5H, m, CH₂, OCH₃); 2.54 (2H, t, *J* 6.0, CH₂); 1.36 (3H, d, *J* 6.0, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 173.4 (C=O ester); 172.7 (C-OH); 171.3 (C=O amide); 170.0 (C=O amide); 162.8 (C=O amide); 140.9 (C Ar); 137.2 (C Ar); 133.3 (CHAr); 130.2 (CHAr); 129.1 (CHAr); 129.0 (CHAr); 125.1 (CHAr); 122.6 (CHAr); 116.2 (CHAr); 115.8 (C Ar); 96.7 (C Ar); 52.3 (OCH₃); 48.0 (CH); 35.9 (CH₂); 35.3 (CH₂); 18.2 (CH₃). Found, %: C, 63.15; H, 5.30; N, 9.61. For C₂₃H₂₃N₃O₆ (437.2). Calculated, %: C, 62.95; H, 5.28; N, 9.49.

Methyl-2-[3-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] 4-methylpentanoate (13c). 0.32 g, Yield 67% white crystals, mp 131-132 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.06 (1H, s, OH); 10.30 (1H, t, *J* 6.0, NH); 8.25 (1H, d, *J* 8.0, ArH); 7.63–7.28 (7H, m, ArH); 6.67 (1H, d, *J* 8.0, ArH); 6.02 (1H, bs, NH); 3.77–3.25 (5H, m, CH₂, OCH₃); 3.26 (2H, q, *J* 6.0, CH₂); 2.53 (2H, t, *J* 6.0, CH₂); 2.29 (2H, t, *J* 6.0, CH₂); 1.65–1.26 (6H, m, 2CH₃). ¹³C NMR spectrum, δ, ppm: 174.0 (C=O ester); 172.8 (C-OH); 171.3 (C=O amide); 170.4 (C=O amide); 162.9 (C=O amide); 140.9 (C Ar); 137.1 (C Ar); 133.4 (CHAr); 130.3 (CHAr); 129.2 (CHAr); 129.1 (CHAr); 125.2 (CHAr); 122.7 (CHAr); 116.1 (CHAr); 115.9 (C Ar); 96.7 (C Ar); 51.5 (OCH₃); 39.4 (C-Leu); 36.4 (CH₂-Leu); 35.5 (CH₂); 33.8 (CH₂); 29.1 (CH₂-Leu); 26.3 (CH₃); 24.4 (CH₃); Found, %: C, 65.00; H, 5.97; N, 8.63. For C₂₆H₂₉N₃O₆ (479.2). Calculated, %: C, 65.12; H, 6.10; N, 8.76.

Methyl-3-[3-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido]propanoate (13d). 0.32 g, Yield 73% white crystals, mp 115-116 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.10 (1H, s, OH); 10.28 (1H, t, *J* 6.0, NH); 8.22 (1H, d, *J* 8.0, ArH); 7.60–7.25 (7H, m, ArH); 6.64 (1H, d, *J* 8.0, ArH); 6.44 (1H, d, *J* 6.0, NH); 3.72–3.45 (7H, m, 2CH₂, OCH₃); 2.53–2.44 (4H, m, 2CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.9 (C=O ester); 172.7 (C-OH); 171.2 (C=O amide); 170.5 (C=O amide); 162.9 (C=O amide); 140.9 (C Ar); 137.2 (C Ar); 133.3 (CHAr); 130.2 (CHAr); 129.1 (CHAr); 129.0 (CHAr); 125.1 (CHAr); 122.6 (CHAr); 116.0 (CHAr); 115.8 (C Ar); 96.7 (C Ar); 51.7 (OCH₃); 36.0 (CH₂); 35.5 (CH₂); 34.9 (CH₂); 33.8 (CH₂). Found, %: C, 63.12; H, 5.22; N, 9.54. For C₂₃H₂₃N₃O₆ (437.2). Calculated, %: C, 63.15; H, 5.30; N, 9.61.

Methyl 2-[3-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino)-propanamido] 2-phenylacetate (13e). 0.41 g, Yield 83% white crystals, mp 190-191 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.07 (1H, s, OH); 10.31 (1H, t, *J* 6.0, NH); 8.26 (1H, d, *J* 8.0, ArH); 7.63–7.29 (12H, m, ArH); 6.76 (1H, d, *J* 8.0, ArH); 6.67 (1H, d, *J* 6.0, NH); 5.61 (1H, d, *J* 6.0, CH), 3.77–3.71 (5H, m, CH₂, OCH₃); 2.60 (2H, t, *J* 6.0, CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 172.7 (C=O ester); 171.3 (C-OH); 171.2 (C=O amide); 169.8 (C=O amide); 162.9 (C=O amide); 140.9 (C Ar); 137.2 (C Ar); 136.4 (C Ar); 133.3 (CHAr); 130.2 (CHAr); 129.1 (CHAr); 129.1 (CHAr); 128.9 (CHAr); 128.5 (CHAr); 127.3 (CHAr); 125.2 (CHAr); 122.6 (CHAr); 116.1 (CHAr); 115.9 (C Ar); 96.8 (C Ar); 56.4 (CH); 52.7 (OCH₃); 36.0 (CH₂); 35.2 (CH₂). Found, %: C, 67.06; H, 4.72; N, 8.28. for C₂₈H₂₅N₃O₆ (499.2). Calculated, %: C, 67.33; H, 5.04; N, 8.41.

Dimethyl 2-[3-((1,2-dihydro-4-hydroxy-2-oxo-1-phenylquinolin-3-yl)carbonylamino) propanamido] 1,5-pentandioate (13f). 0.25 g, Yield 49% white crystals, mp 88-89 °C. ¹H NMR spectrum, (300 MHz, CDCl₃), δ, ppm (*J*, Hz): 17.11 (1H, s, OH); 10.26 (1H, t, *J* 6.0, NH); 8.16 (1H, d, *J* 8.0, ArH); 7.59–7.25 (7H, m, ArH); 6.76 (1H, d, *J* 8.0, ArH); 6.60 (1H, d, *J* 6.0, NH); 4.58 (1H, q, *J* 6.0, CH); 3.72–3.55 (7H, m, CH₂, 2OCH₃); 2.52 (2H, t, *J* 6.0, CH₂); 2.37–1.94 (4H, m, 2CH₂). ¹³C NMR spectrum, δ, ppm: 173.2 (C=O ester); 172.7 (C=O ester); 172.2 (C-OH); 171.2 (C=O amide); 170.6 (C=O amide); 162.8 (C=O amide); 140.9 (C Ar); 137.2 (C Ar); 133.3 (CHAr); 130.3 (CHAr); 130.2 (CHAr); 129.0 (CHAr); 125.1 (CHAr); 122.5 (CHAr); 116.0 (CHAr); 115.9 (C Ar); 96.7 (C Ar); 52.4 (OCH₃);

52.1 (OCH₃); 51.6 (CH); 35.8 (CH₂); 35.3 (CH₂); 30.0 (CH₂); 27.1 (CH₂). Found, %: C, 61.02; H, 5.17; N, 8.06. For C₂₆H₂₇N₃O₈ (509.2). Calculated, %: C, 61.29; H, 5.34; N, 8.25.

References

1. Jones, G. *Chemistry of Heterocyclic Compounds: Quinolines*, Part I, Volume 32, John Wiley and Sons, 2008.
2. Acharya, B. N.; Thavaselvam, D.; Kaushik, M. B.; *Med. Chem. Res.* **2008**, *17*, 487.
<https://doi.org/10.1007/s00044-008-9092-5>
3. Gootz T. D.; Brighty K. E. Chemistry and mechanism of action of the quinolone antibacterials. In: Andriole VT, Ed. *The Quinolones*. San Diego: Academic Press, 1998, pp29-80.
4. Emami S.; Shafiee A.; Foroumadi A. *Iran. J. Pharm. Res.* **2005**, *3*, 123.
5. Keri R. S.; Patil S. A. *Biomed Pharmacother.* **2014**, *68*(8), 1161.
<https://doi.org/10.1016/j.biopha.2014.10.007>
6. Sliman, F.; Blairvacq, M.; Durieu, E.; Meijer, L.; Rodrigo, J.; Desmaële, D. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2801.
<https://doi.org/10.1016/j.bmcl.2010.03.061>
7. Zhang J.; Ke X.; Tu C.; Lin J.; Ding J.; Lin, L.; Fun H. K.; You X.; Guo Z. *Biometals.* **2003** *16*, 485.
<https://doi.org/10.1023/A:1022577420708>
8. Abadi, A. H., Hegazy, G. H., Zaher, A. A. E. *Bioorg. Med. Chem.* **2005**, *13*, 5759.
<https://doi.org/10.1016/j.bmc.2005.05.053>
9. Baba A.; Kawamura N.; Makino H.; Ohta Y.; Taketomi S.; Sohda T. *J. Med. Chem.* **1996**, *39*, 5176.
<https://doi.org/10.1021/jm9509408>
10. Tsuji K.; Spears G. W. Nakamura K.; Tojo T.; Seki N.; Sugiyama A.; Matsuo M. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 85.
[https://doi.org/10.1016/S0960-894X\(01\)00671-0](https://doi.org/10.1016/S0960-894X(01)00671-0)
11. Bachiller M. I. F.; Perez C.; Munoz G.C.G.; Conde S.; Lopez M.G.; Villarroya M.; Garcia A.G.; Franco M. I. R. *J. Med. Chem.* **2010**, *53*, 4927.
<https://doi.org/10.1021/jm100329g>
12. Kalland, T. *Cancer Res.* **1986**, *46*, 3018.
13. Robinson C.; Castaner J. *Drugs Future* **1995**, *20*, 19.
<https://doi.org/10.1358/dof.1995.020.01.280162>
14. Anderson O.; Lycke J.; Tollesson P. O.; Svenningsson A.; Runmarker B.; Linde A. S.; Astrom M.; Gjorstrup P.; Ekholm S. *Neurology* **1996**, *47*, 895.
<https://doi.org/10.1212/WNL.47.4.895>
15. Karussis D. M.; Meiner Z.; Lehmann D.; Gomori J.-M.; Schwaz A.; Linde A.; Abramsky O. *Neurology* **1996**, *47*, 341.
<https://doi.org/10.1212/WNL.47.2.341>
16. Townsend C. A.; Brown A. M. *J. Am. Chem. Soc.* **1983**, *105*(4), 913.
<https://doi.org/10.1021/ja00342a046>
17. Moloney M. G. *Nat. Prod. Rep.* **1999**, *16*(4), 485.
<https://doi.org/10.1039/a800247i>

18. Allen C. F. H.; McKee G. H. W. *Org. Synth.* **1939**, *19*, 6.
<https://doi.org/10.15227/orgsyn.019.0006>
19. Cappola G. M.; Hartmann, G. E. *J Heterocyclic chemistry* **1979**, *16*, 1605.
20. Jönsson S.; Andersson G.; Fex T.; Fristedt T.; Hedlund G.; Jansson K.; Abramo L.; Fritzson I.; Pekarski O.; Runström A.; Sandin H.; Thuvesson I.; Björk A. *J. Med. Chem.* **2004**, *47*, 2075.